Addex chief executive Tim Dyer told news agency AWP that the return of a GABAB research program from former partner Indivior is a welcome development.
Indivior initially paid $5 million for the program in 2018 and subsequently invested more than $20 million, with comparable internal R&D costs, according to Dyer. Addex will now receive the full value of those investments.
The company announced that it has regained worldwide rights to all GABAB drug candidates that were part of the partnership. The hand‑over follows the planned merger of Indivior's parent company with Supernus Pharmaceuticals, which led to a restructuring and the shutdown of Indivior's research activities.
The returned candidate is aimed at treating substance‑use disorders and is ready to enter Phase I clinical trials, though Addex must now secure the necessary funding to advance it.
Addex also maintains a separate GABAB program targeting chronic cough. The firm said it will explore strategic options for both programs, including new collaborations, continued internal development, or later partnership arrangements.
